Cetera Advisor Networks’s BridgeBio Pharma BBIO Stock Holding History

Cetera Advisor Networks’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-47,528	Closed	-$362K	–	2602
2022 Q4	$362K	Buy	47,528 +2,448	+5%	+$23.4K	﹤0.01%	1867
2022 Q3	$448K	Buy	45,080 +21,231	+89%	+$221K	0.01%	1358
2022 Q2	$216K	Buy	+23,849	New	+$199K	﹤0.01%	1806

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Cetera Advisor Networks's BBIO Position: Q1 2023 in Review

Cetera Advisor Networks sold out of BridgeBio Pharma (BBIO) in Q1 2023, closing a stake of 47,528 shares — an estimated $362K sold.

Cetera Advisor Networks first reported a position in BBIO in Q2 2022 and held it in 3 quarters. The position peaked at $448K in Q3 2022. 213 funds tracked by Wall St. Rank hold BBIO as of Q1 2023.

Cetera Advisor Networks reported no remaining BridgeBio Pharma position as of Q1 2023 after selling out during the quarter.
Cetera Advisor Networks sold 47,528 BridgeBio Pharma shares in Q1 2023, an estimated $362K.
Cetera Advisor Networks first reported a position in BridgeBio Pharma in Q2 2022 and held it in 3 quarters.
Cetera Advisor Networks's BridgeBio Pharma position peaked at $448K in Q3 2022.
213 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2023.

Based on Cetera Advisor Networks's 13F filing for Q1 2023, filed 15 May 2023.